ArticleThoracic cancer2021
The LungVision navigational platform for peripheral lung nodule biopsy and the added value of cryobiopsy.
Article in Thoracic cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Real-Time AI-Augmented Fluoroscopic Navigation for Intraoperative Pulmonary Nodule Localization: Prospective Observational Pilot Study.JMIR formative research · 2026Observational
- Opportunities for Interventional Radiology in Transbronchial Interventions.Cardiovascular and interventional radiology · 2026Review
- Robotic-assisted bronchoscopy combined with digital tomosynthesis for pulmonary nodules characterization: a single center experience.Frontiers in medicine · 2026Article
- Digital tomosynthesis for navigational bronchoscopy: a clinical practice review.Journal of thoracic disease · 2025Review
- Feasibility of a Modified Bronchoscopic Transparenchymal Nodule Access Technique ('Essen Tunnel') for Improving the Diagnosis of Intraparenchymal Pulmonary Lesions.Respirology (Carlton, Vic.) · 2025Article
- Ultrathin Bronchoscopy Without Virtual Navigation for Diagnosis of Peripheral Lung Lesions.Lung · 2024Article
- State of the art: peripheral diagnostic bronchoscopy.Journal of thoracic disease · 2024Review
- New developments in the imaging of lung cancer.Breathe (Sheffield, England) · 2024Review
- Digital Tomosynthesis: Review of Current Literature and Its Impact on Diagnostic Bronchoscopy.Diagnostics (Basel, Switzerland) · 2023Review
- Robotic Bronchoscopy: Review of Three Systems.Life (Basel, Switzerland) · 2023Review
- Endoscopic Technologies for Peripheral Pulmonary Lesions: From Diagnosis to Therapy.Life (Basel, Switzerland) · 2023Review
- Radial Endobronchial Ultrasound-guided Transbronchial CryobiopsyThe open respiratory medicine journal · 2023Article
- Advances in Diagnostic Bronchoscopy.Diagnostics (Basel, Switzerland) · 2021Review
- The LungVision navigational platform for peripheral lung nodule biopsy and the added value of cryobiopsy.Thoracic cancer · 2021Article
- Artificial Intelligence in Interventional Pulmonology.Therapeutic advances in pulmonary and critical care medicineReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe LungVision system is a novel augmented-fluoroscopy-based real-time navigation and guidance technology for bronchoscopy that can be integrated with any standard biopsy tool, including the cryoprobe, to enable real-time visualization and localization of pulmonary nodules.
objectivesTo evaluate the diagnostic yield and safety among patients undergoing peripheral pulmonary nodule biopsy with the LungVision system.
methodsThis prospective, single-center study was conducted at Rabin Medical Center in Israel. All patients that underwent peripheral pulmonary nodule biopsy with the LungVision system from January 2016 to August 2020 were included. All procedures were performed under moderate sedation. The primary outcome was tissue diagnosis by either identification of malignant cells or benign diagnosis. Secondary outcomes were safety and the added value of cryobiopsy.
resultsSixty-three procedures were performed during the study period. Median lesion size (interquartile range) was 25.0 mm (18-28 mm). The diagnostic yield overall was 27/33 (81.8%) and for lesions smaller than 20 mm was 13/18 (72.2%). In nine cases the transbronchial cryobiopsy showed tissue with malignant cells that were not found in any other biopsy material taken with other sampling tools. One patient was treated with a chest tube for a pneumothorax. No other major complications were reported.
conclusionsThe LungVision system showed good feasibility and safety for peripheral pulmonary nodule biopsy. The system is compatible with all biopsy tools, including the cryoprobe. Randomized controlled trials are needed to accurately ascertain its diagnostic yield.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.